HRP20220616T1 - Genetski modificirani miš koji eksprimira kimerne molekule glavnog kompleksa histokompatibilnosti (mhc) ii - Google Patents
Genetski modificirani miš koji eksprimira kimerne molekule glavnog kompleksa histokompatibilnosti (mhc) ii Download PDFInfo
- Publication number
- HRP20220616T1 HRP20220616T1 HRP20220616TT HRP20220616T HRP20220616T1 HR P20220616 T1 HRP20220616 T1 HR P20220616T1 HR P20220616T T HRP20220616T T HR P20220616TT HR P20220616 T HRP20220616 T HR P20220616T HR P20220616 T1 HRP20220616 T1 HR P20220616T1
- Authority
- HR
- Croatia
- Prior art keywords
- mhc
- rodent
- human
- polypeptide
- chimeric
- Prior art date
Links
- 108700018351 Major Histocompatibility Complex Proteins 0.000 title 1
- 241000699670 Mus sp. Species 0.000 title 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 title 1
- 241000283984 Rodentia Species 0.000 claims 43
- 229920001184 polypeptide Polymers 0.000 claims 32
- 108090000765 processed proteins & peptides Proteins 0.000 claims 32
- 102000004196 processed proteins & peptides Human genes 0.000 claims 32
- 238000000034 method Methods 0.000 claims 10
- 239000002773 nucleotide Substances 0.000 claims 8
- 125000003729 nucleotide group Chemical group 0.000 claims 8
- 101100263837 Bovine ephemeral fever virus (strain BB7721) beta gene Proteins 0.000 claims 7
- 101100316840 Enterobacteria phage P4 Beta gene Proteins 0.000 claims 7
- 101150087698 alpha gene Proteins 0.000 claims 7
- 239000000427 antigen Substances 0.000 claims 7
- 108091007433 antigens Proteins 0.000 claims 7
- 102000036639 antigens Human genes 0.000 claims 7
- 108010046732 HLA-DR4 Antigen Proteins 0.000 claims 5
- 210000004027 cell Anatomy 0.000 claims 4
- 230000001086 cytosolic effect Effects 0.000 claims 4
- 230000001105 regulatory effect Effects 0.000 claims 4
- 108010010378 HLA-DP Antigens Proteins 0.000 claims 2
- 102000015789 HLA-DP Antigens Human genes 0.000 claims 2
- 108010062347 HLA-DQ Antigens Proteins 0.000 claims 2
- 108091008874 T cell receptors Proteins 0.000 claims 2
- 230000005867 T cell response Effects 0.000 claims 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- 108010067802 HLA-DR alpha-Chains Proteins 0.000 claims 1
- 108010053491 HLA-DR beta-Chains Proteins 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 150000007523 nucleic acids Chemical group 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Claims (10)
1. Postupak za identifikaciju antigena koji generira CD4+ odgovor T stanice kod čovjeka, naznačen time, da obuhvaća:
izlaganje glodavca navodnom antigenu,
omogućavanje glodavcu da generira imunosni odgovor,
otkrivanje CD4+ odgovora T stanice koja je specifična za antigen; i
identifikaciju antigena,
pri čemu glodavac sadrži:
(i) na endogenom MHC II α genskom lokusu, nukleotidni slijed koji kodira kimerni ljudski/glodavački MHC II α polipeptid, i
(ii) na endogenom MHC II β genskom lokusu, nukleotidni slijed koji kodira kimerni ljudski/glodavački MHC II β polipeptid,
pri čemu ljudski dio kimernog ljudskog/glodavačkog MHC II α polipeptida, sadrži ljudske MHC II α1 i α2 domene, i ljudski dio kimernog ljudskog/glodavačkog MHC II β polipeptida, sadrži ljudske MHC II β1 i β2 domene,
dok glodavac eksprimira funkcionalni kimerni MHC II kompleks koji sadrži kimerni ljudski/glodavački MHC II α polipeptid i kimerni ljudski/glodavački MHC II β polipeptid, na površini stanice glodavca.
2. Postupak za identifikaciju varijabilne domene receptora T stanice koji prepoznaje antigen koji je predstavljen u kontekstu ljudskog MHC II, naznačen time, da obuhvaća:
izlaganje glodavca antigenu,
omogućavanje glodavcu da generira imunosni odgovor, i
izoliranje iz glodavca slijeda nukleinske kiseline koji kodira varijabilnu domenu receptora T stanice koji se veže na MHC II ograničeni antigen,
pri čemu glodavac sadrži:
(i) na endogenom MHC II α genskom lokusu, nukleotidni slijed koji kodira kimerni ljudski/glodavački MHC II α polipeptid, i
(ii) na endogenom MHC II β genskom lokusu, nukleotidni slijed koji kodira kimerni ljudski/glodavački MHC II β polipeptid,
pri čemu ljudski dio kimernog ljudskog/glodavačkog MHC II α polipeptida, sadrži ljudske MHC II α1 i α2 domene, i ljudski dio kimernog ljudskog/glodavačkog MHC II β polipeptida, sadrži ljudske MHC II β1 i β2 domene,
dok glodavac eksprimira funkcionalni kimerni MHC II kompleks koji sadrži kimerni ljudski/glodavački MHC II α polipeptid i kimerni ljudski/glodavački MHC II β polipeptid, na površini stanice glodavca.
3. Postupak prema patentnom zahtjevu 1 ili zahtjevu 2, naznačen time, da se nukleotidni slijed koji kodira kimerni ljudski/glodavački MHC II α polipeptid, eksprimira pod reguliranim upravljanjem endogenog glodavačkog MHC II α promotora i regulacijskih elemenata, i nukleotidni slijed koji kodira kimerni ljudski/glodavački MHC II β polipeptid se eksprimira pod reguliranim upravljanjem endogenog glodavačkog MHC II β promotora i regulacijskih elemenata.
4. Postupak prema patentnom zahtjevu 1 ili zahtjevu 2, naznačen time, da glodavački dio kimernog ljudskog/glodavačkog MHC II α polipeptida, sadrži transmembransku i citoplazmatsku domenu endogenog glodavačkog MHC II α polipeptida, i glodavački dio kimernog ljudskog/glodavačkog MHC II β polipeptida, sadrži transmembransku i citoplazmatsku domenu endogenog glodavačkog MHC II β polipeptida.
5. Postupak prema patentnom zahtjevu 1 ili zahtjevu 2, naznačen time, da ljudski dio kimernog ljudskog/glodavačkog MHC II α polipeptida, kodira genski lanac HLA razreda II α odabranog iz skupine koju čine HLA-DR α genski lanac, HLA-DQ α genski lanac, i HLA-DP α genski lanac, i ljudski dio kimernog ljudskog/glodavačkog MHC II β polipeptida, kodira genski lanac HLA razreda II β odabranog iz skupine koju čine HLA-DR β genski lanac, HLA-DQ β genski lanac, i HLA-DP β genski lanac.
6. Postupak prema patentnom zahtjevu 5, naznačen time, da ljudski dio kimernog ljudskog/glodavačkog MHC II α polipeptida, kodira putem ljudskog HLA-DR4 α genskog lanca, i ljudski dio kimernog ljudskog/glodavačkog MHC II β polipeptida, kodira HLA-DR4 β genski lanac.
7. Postupak prema patentnom zahtjevu 7, naznačen time, da glodavac jest miš.
8. Postupak prema patentnom zahtjevu 1 ili zahtjevu 2, naznačen time, da glodavac je miš i da se glodavačke dijelove kimernih MHC II α i β polipeptida kodiraju mišji H-2E α i β gena.
9. Postupak prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time, da glodavac je miš koji na endogenom mišjem MHC II lokusu sadrži prvi nukleotidni slijed koji kodira kimerni ljudski/mišji MHC II α polipeptid i drugi nukleotidni slijed koji kodira kimerni ljudski/mišji MHC II β polipeptid,
pri čemu ljudski dio kimernog MHC II α polipeptida sadrži α1 i α2 domene koje kodirana ljudski HLA-DR4 α genski lanca, i ljudski dio kimernog MHC II β polipeptida sadrži β1 i β2 domene koje kodira ljudski HLA-DR4 β genski lanac,
dok mišji dio kimernog MHC II α polipeptida, sadrži transmembransku i citoplazmatsku domenu mišjeg H-2E α lanca, i mišji dio kimernog MHC II β polipeptida, sadrži transmembransku i citoplazmatsku domenu mišjeg H-2E β lanca,
i pritom miš eksprimira funkcionalni kimerni kompleks HLA-DR4/H-2E MHC II koji sadrži kimerni ljudski/mišji MHC II α polipeptid i kimerni ljudski/mišji MHC II β polipeptid, na površini mišje stanice.
10. Postupak prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time, da glodavac na površini stanice ne eksprimira funkcionalne endogene MHC II polipeptide sa njihovih endogenih glodavačkih MHC II lokusa.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161552584P | 2011-10-28 | 2011-10-28 | |
EP19189533.3A EP3590332B1 (en) | 2011-10-28 | 2012-10-26 | Genetically modified mice expressing chimeric major histocompatibility complex (mhc) ii molecules |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20220616T1 true HRP20220616T1 (hr) | 2022-06-24 |
Family
ID=47430036
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20220616TT HRP20220616T1 (hr) | 2011-10-28 | 2012-10-26 | Genetski modificirani miš koji eksprimira kimerne molekule glavnog kompleksa histokompatibilnosti (mhc) ii |
HRP20171327TT HRP20171327T1 (hr) | 2011-10-28 | 2017-09-04 | Genetski modificirani miševi s ekspresijom kimernih molekula s glavnim sustavom tkivne podudarnosti (mhc) skupine ii |
HRP20200305TT HRP20200305T1 (hr) | 2011-10-28 | 2020-02-24 | Genetski modificirani miševi koji eksprimiraju kimerne molekule glavnog histokompatibilnog kompleksa (mhc) ii |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20171327TT HRP20171327T1 (hr) | 2011-10-28 | 2017-09-04 | Genetski modificirani miševi s ekspresijom kimernih molekula s glavnim sustavom tkivne podudarnosti (mhc) skupine ii |
HRP20200305TT HRP20200305T1 (hr) | 2011-10-28 | 2020-02-24 | Genetski modificirani miševi koji eksprimiraju kimerne molekule glavnog histokompatibilnog kompleksa (mhc) ii |
Country Status (25)
Country | Link |
---|---|
US (6) | US8847005B2 (hr) |
EP (4) | EP2770822B9 (hr) |
JP (2) | JP6285361B2 (hr) |
KR (2) | KR101926442B1 (hr) |
CN (3) | CN108401986B (hr) |
AU (4) | AU2012327205B2 (hr) |
BR (1) | BR112014009941B1 (hr) |
CA (1) | CA2852962C (hr) |
CY (2) | CY1119283T1 (hr) |
DK (3) | DK2770822T3 (hr) |
ES (3) | ES2914374T3 (hr) |
HK (2) | HK1196999A1 (hr) |
HR (3) | HRP20220616T1 (hr) |
HU (2) | HUE034374T2 (hr) |
IL (3) | IL231895B (hr) |
IN (1) | IN2014CN03892A (hr) |
LT (3) | LT2770822T (hr) |
MX (1) | MX355726B (hr) |
PL (3) | PL2770822T3 (hr) |
PT (3) | PT3590332T (hr) |
RS (3) | RS63220B1 (hr) |
RU (1) | RU2660564C2 (hr) |
SG (3) | SG10201510056SA (hr) |
SI (3) | SI2770822T1 (hr) |
WO (1) | WO2013063340A1 (hr) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008054865A2 (en) | 2006-04-26 | 2008-05-08 | L-3 Communications Security And Detection Systems, Inc. | Multi-source surveillance systems |
KR101926442B1 (ko) | 2011-10-28 | 2018-12-12 | 리제너론 파아마슈티컬스, 인크. | 키메라 주요 조직적합성 복합체 (mhc) ii 분자들을 발현하는 유전자 변형된 마우스 |
EP2818478B1 (en) | 2011-10-28 | 2017-02-01 | Regeneron Pharmaceuticals, Inc. | Humanized IL-6 and IL-6 receptor |
US9043996B2 (en) | 2011-10-28 | 2015-06-02 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex animals |
EP2958938B1 (en) | 2013-02-20 | 2019-04-17 | Regeneron Pharmaceuticals, Inc. | Mice expressing humanized t-cell co-receptors |
SI2958937T1 (sl) * | 2013-02-22 | 2018-12-31 | Regeneron Pharmaceuticals, Inc. | Miš, ki izraža humanizirani poglavitni histokompatibilnostni kompleks |
US20150342163A1 (en) | 2013-02-22 | 2015-12-03 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex mice |
CN105208855B (zh) * | 2013-03-11 | 2018-04-27 | 瑞泽恩制药公司 | 表达嵌合的主要组织相容性复合物(mhc)ii类分子的转基因小鼠 |
IL297607B2 (en) | 2013-09-23 | 2024-01-01 | Regeneron Pharma | Non-human animals with a humanized gene for SIGNAL-REGULATORY PROTEIN |
KR102376041B1 (ko) * | 2013-10-15 | 2022-03-18 | 리제너론 파마슈티칼스 인코포레이티드 | 인간화된 il-15 동물 |
SG11201604886WA (en) | 2014-04-08 | 2016-07-28 | Regeneron Pharma | Non-human animals having humanized fc-gamma receptors |
NO2785538T3 (hr) | 2014-05-07 | 2018-08-04 | ||
EP3157956B1 (en) * | 2014-06-19 | 2020-02-05 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized programmed cell death 1 gene |
AU2015317370A1 (en) | 2014-09-19 | 2017-03-23 | Regeneron Pharmaceuticals, Inc. | Chimeric antigen receptors |
LT3689140T (lt) | 2014-11-24 | 2022-08-25 | Regeneron Pharmaceuticals, Inc. | Gyvūnai, išskyrus žmones, ekspresuojantys humanizuotą cd3 kompleksą |
FI3850946T3 (fi) | 2014-12-05 | 2023-12-28 | Regeneron Pharma | Ei-ihmiseläimiä, joilla on humanisoitu erilaistumisklusterin 47 geeni |
AU2016246698B2 (en) | 2015-04-06 | 2022-06-02 | Regeneron Pharmaceuticals, Inc. | Humanized T cell mediated immune responses in non-human animals |
MX2018005389A (es) | 2015-11-20 | 2018-09-05 | Regeneron Pharma | Animales no humanos que tienen un gen 3 de activacion linfocitaria humanizado. |
EP3411392B1 (en) * | 2016-02-04 | 2021-12-29 | Regeneron Pharmaceuticals, Inc. | Non-human animals having an engineered angptl8 gene |
CN109068621B (zh) | 2016-02-29 | 2021-07-20 | 再生元制药公司 | 具有人源化的tmprss基因的啮齿类动物 |
CN116458475A (zh) | 2016-06-03 | 2023-07-21 | 瑞泽恩制药公司 | 表达外源末端脱氧核苷酸转移酶的非人动物 |
JP7361031B2 (ja) | 2017-11-30 | 2023-10-13 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ヒト化trkb遺伝子座を含む非ヒト動物 |
WO2019190922A1 (en) | 2018-03-24 | 2019-10-03 | Regeneron Pharmaceuticals, Inc. | Genetically modified non-human animals for generating therapeutic antibodies against peptide-mhc complexes, methods of making and uses thereof |
KR20210004994A (ko) | 2018-03-26 | 2021-01-13 | 리제너론 파마슈티칼스 인코포레이티드 | 치료제를 시험하기 위한 인간화된 설치류 |
KR20210031868A (ko) | 2018-07-16 | 2021-03-23 | 리제너론 파마슈티칼스 인코포레이티드 | Ditra 질환의 비인간 동물 모델 및 이의 용도 |
CA3155234A1 (en) * | 2019-10-22 | 2021-04-29 | Megan Sykes | Transgenic swine, methods of making and uses thereof, and methods of making human immune system mice |
JP2023504172A (ja) | 2019-12-02 | 2023-02-01 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ペプチド-mhc iiタンパク質構築物およびそれらの使用 |
BR112023018874A2 (pt) | 2021-03-31 | 2023-10-03 | Regeneron Pharma | Camundongos geneticamente modificados compreendendo componentes do sistema imunológico celular humanizado com diversidade melhorada do repertório de tcrb |
WO2023240124A1 (en) | 2022-06-07 | 2023-12-14 | Regeneron Pharmaceuticals, Inc. | Pseudotyped viral particles for targeting tcr-expressing cells |
WO2023240109A1 (en) | 2022-06-07 | 2023-12-14 | Regeneron Pharmaceuticals, Inc. | Multispecific molecules for modulating t-cell activity, and uses thereof |
WO2024064860A1 (en) | 2022-09-22 | 2024-03-28 | Regeneron Pharmaceuticals, Inc. | Genetically modified mice expressing components of human cellular immune system |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0437576B1 (en) | 1989-07-25 | 2002-07-03 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
US5413923A (en) | 1989-07-25 | 1995-05-09 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
US5574205A (en) | 1989-07-25 | 1996-11-12 | Cell Genesys | Homologous recombination for universal donor cells and chimeric mammalian hosts |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
GB9100481D0 (en) | 1991-01-10 | 1991-02-20 | Inst Nat Sante Rech Med | Genetically engineered mice |
AU2661692A (en) | 1991-09-19 | 1993-04-27 | President And Fellows Of Harvard College | Transgenic mhc class i and class ii antigen-deficient mammals |
EP0663952A4 (en) | 1992-09-11 | 1997-06-11 | Univ California | TRANSGENIC NON-HUMAN ANIMALS WITH TARGETED INTERRUPTED TRANSDUCTION GENES IN LYMPHOCYTES. |
US5523226A (en) | 1993-05-14 | 1996-06-04 | Biotechnology Research And Development Corp. | Transgenic swine compositions and methods |
GB9315303D0 (en) | 1993-07-23 | 1993-09-08 | Zeneca Ltd | Polypeptide |
US5965787A (en) | 1995-08-31 | 1999-10-12 | Mayo Foundation For Medical Education And Research | HLA-DRBI peptides with specific binding affinity for HLA-DQ molecules: prevention and treatment of rheumatoid arthritis |
US6002066A (en) | 1996-01-16 | 1999-12-14 | Ortho Pharmaceutical Corp. | H2-M modified transgenic mice |
WO1997032603A1 (en) | 1996-03-05 | 1997-09-12 | The Scripps Research Institute | Recombinant constructs encoding t cell receptors specific for human hla-restricted tumor antigens |
ES2301183T3 (es) | 1996-12-03 | 2008-06-16 | Amgen Fremont Inc. | Anticuerpo completamente humano que se une al receptor del egfr. |
AU741130B2 (en) | 1997-09-16 | 2001-11-22 | Oregon Health Sciences University | Recombinant MHC molecules useful for manipulation of antigen-specific T-cells |
US6372955B1 (en) | 1998-02-17 | 2002-04-16 | Ortho Mcneil Pharmaceutical, Inc. | Methods for Producing B cells and antibodies from H2-O modified transgenic mice |
CA2325721A1 (en) * | 1998-03-30 | 1999-10-07 | Research Development Foundation | Corticotropin releasing factor receptor 1-deficient mice |
AU1023401A (en) | 1999-10-12 | 2001-04-23 | Institut Pasteur | Design of a polyepitopic construct for the induction of hla-a2.1 restricted hiv 1 specific ctl responses using hhd mice |
US7067308B1 (en) * | 2000-03-28 | 2006-06-27 | Bioagri Corporation | Vector for genetically modifying non-human animals |
WO2002000933A2 (en) | 2000-06-23 | 2002-01-03 | Interleukin Genetics, Inc. | Screening assays for identifying modulators of the inflammatory or immune responses |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
US7105348B2 (en) | 2000-10-31 | 2006-09-12 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
US6586251B2 (en) | 2000-10-31 | 2003-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
AU2002222610A1 (en) | 2000-12-13 | 2002-06-24 | Sumitomo Pharmaceuticals Company, Limited | Transgenic animal expressing hla-a24 and utilization thereof |
AU2002246733B2 (en) | 2000-12-19 | 2007-09-20 | Altor Bioscience Corporation | Transgenic animals comprising a humanized immune system |
FR2827302B1 (fr) * | 2001-07-13 | 2003-10-10 | Genoway | Cellule et animal transgenique modelisant la presentation antigenique humaine et leurs utilisations |
US20040072262A1 (en) | 2002-10-11 | 2004-04-15 | Montero-Julian Felix A. | Methods and systems for detecting MHC class I binding peptides |
US7663017B2 (en) * | 2003-07-30 | 2010-02-16 | Institut Pasteur | Transgenic mice having a human major histocompatability complex (MHC) phenotype, experimental uses and applications |
DE10347710B4 (de) * | 2003-10-14 | 2006-03-30 | Johannes-Gutenberg-Universität Mainz | Rekombinante Impfstoffe und deren Verwendung |
JP4857450B2 (ja) | 2004-03-09 | 2012-01-18 | 財団法人名古屋産業科学研究所 | ヒト関節リウマチの病態を再現するトランスジェニック非ヒト哺乳動物 |
PT1802193E (pt) | 2004-10-19 | 2014-06-23 | Regeneron Pharma | Método para gerar um murganho homozigótico para uma modificação genética |
EP1878342A1 (en) | 2006-07-13 | 2008-01-16 | Institut Pasteur | Immunodeficient mice transgenic for HLA class I and HLA class II molecules and their uses |
EP1878798A1 (en) | 2006-07-13 | 2008-01-16 | Institut Pasteur | Method of producing a multichimeric mouse and applications to study the immunopathogenesis of human tissue-specific pathologies |
HU0700534D0 (en) | 2006-11-24 | 2007-10-29 | Mezoegazdasagi Biotechnologiai | Transgenic animal with enhanced immune response and method for the preparation thereof |
NO347649B1 (no) | 2006-12-14 | 2024-02-12 | Regeneron Pharma | Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse. |
US20090271884A1 (en) | 2008-03-07 | 2009-10-29 | Regeneron Pharmaceuticals, Inc. | ES Cell-Derived Mice From Diploid Host Embryo Injection |
US20090328240A1 (en) | 2008-06-24 | 2009-12-31 | Sing George L | Genetically modified mice as predictors of immune response |
DK3241435T3 (da) | 2009-07-08 | 2021-08-23 | Kymab Ltd | Dyremodeller og terapeutiske molekyler |
CN101695587B (zh) * | 2009-10-21 | 2012-08-29 | 上海中山医疗科技发展公司 | 一种基因修饰及调控的内皮祖细胞捕获支架的制备方法 |
BR112013000985A2 (pt) | 2010-07-15 | 2017-09-05 | Technion Res & Dev Foundation | Entidades isoladas de alta afinidade com especificidade semelhante à do receptor de célula t em relação a complexos nativos de mhc classe ii e peptídeos autoantigênicos de descarboxilase do ácido glutâmico (gad) |
US9557323B2 (en) | 2010-09-24 | 2017-01-31 | The United States Of America As Represented By The Secretary Of The Navy | Humanized transgenic mouse model |
US9043996B2 (en) | 2011-10-28 | 2015-06-02 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex animals |
KR101926442B1 (ko) | 2011-10-28 | 2018-12-12 | 리제너론 파아마슈티컬스, 인크. | 키메라 주요 조직적합성 복합체 (mhc) ii 분자들을 발현하는 유전자 변형된 마우스 |
EP2958938B1 (en) | 2013-02-20 | 2019-04-17 | Regeneron Pharmaceuticals, Inc. | Mice expressing humanized t-cell co-receptors |
US20150342163A1 (en) | 2013-02-22 | 2015-12-03 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex mice |
SI2958937T1 (sl) | 2013-02-22 | 2018-12-31 | Regeneron Pharmaceuticals, Inc. | Miš, ki izraža humanizirani poglavitni histokompatibilnostni kompleks |
CN105208855B (zh) | 2013-03-11 | 2018-04-27 | 瑞泽恩制药公司 | 表达嵌合的主要组织相容性复合物(mhc)ii类分子的转基因小鼠 |
AU2016246698B2 (en) | 2015-04-06 | 2022-06-02 | Regeneron Pharmaceuticals, Inc. | Humanized T cell mediated immune responses in non-human animals |
-
2012
- 2012-10-26 KR KR1020147014315A patent/KR101926442B1/ko active IP Right Grant
- 2012-10-26 LT LTEP12806199.1T patent/LT2770822T/lt unknown
- 2012-10-26 PL PL12806199T patent/PL2770822T3/pl unknown
- 2012-10-26 EP EP12806199.1A patent/EP2770822B9/en active Active
- 2012-10-26 HU HUE12806199A patent/HUE034374T2/en unknown
- 2012-10-26 HR HRP20220616TT patent/HRP20220616T1/hr unknown
- 2012-10-26 SI SI201231056T patent/SI2770822T1/sl unknown
- 2012-10-26 RS RS20220473A patent/RS63220B1/sr unknown
- 2012-10-26 DK DK12806199.1T patent/DK2770822T3/en active
- 2012-10-26 EP EP19189533.3A patent/EP3590332B1/en active Active
- 2012-10-26 CA CA2852962A patent/CA2852962C/en active Active
- 2012-10-26 SG SG10201510056SA patent/SG10201510056SA/en unknown
- 2012-10-26 CN CN201810239986.6A patent/CN108401986B/zh active Active
- 2012-10-26 SI SI201231999T patent/SI3590332T1/sl unknown
- 2012-10-26 KR KR1020187034955A patent/KR102113108B1/ko active IP Right Grant
- 2012-10-26 PT PT191895333T patent/PT3590332T/pt unknown
- 2012-10-26 RU RU2014116577A patent/RU2660564C2/ru active
- 2012-10-26 LT LTEP17171524.6T patent/LT3272214T/lt unknown
- 2012-10-26 ES ES19189533T patent/ES2914374T3/es active Active
- 2012-10-26 IN IN3892CHN2014 patent/IN2014CN03892A/en unknown
- 2012-10-26 CN CN201280065075.7A patent/CN104039133B/zh active Active
- 2012-10-26 MX MX2014004896A patent/MX355726B/es active IP Right Grant
- 2012-10-26 ES ES12806199.1T patent/ES2640241T3/es active Active
- 2012-10-26 EP EP17171524.6A patent/EP3272214B1/en active Active
- 2012-10-26 SG SG10201909638U patent/SG10201909638UA/en unknown
- 2012-10-26 AU AU2012327205A patent/AU2012327205B2/en active Active
- 2012-10-26 WO PCT/US2012/062029 patent/WO2013063340A1/en active Application Filing
- 2012-10-26 SI SI201231738T patent/SI3272214T1/sl unknown
- 2012-10-26 SG SG11201400938UA patent/SG11201400938UA/en unknown
- 2012-10-26 JP JP2014539027A patent/JP6285361B2/ja active Active
- 2012-10-26 CN CN201810239690.4A patent/CN108707608A/zh active Pending
- 2012-10-26 PL PL19189533T patent/PL3590332T3/pl unknown
- 2012-10-26 PT PT171715246T patent/PT3272214T/pt unknown
- 2012-10-26 DK DK17171524.6T patent/DK3272214T3/da active
- 2012-10-26 US US13/661,116 patent/US8847005B2/en active Active
- 2012-10-26 PT PT128061991T patent/PT2770822T/pt unknown
- 2012-10-26 LT LTEP19189533.3T patent/LT3590332T/lt unknown
- 2012-10-26 RS RS20170897A patent/RS56330B1/sr unknown
- 2012-10-26 RS RS20200224A patent/RS59997B1/sr unknown
- 2012-10-26 BR BR112014009941-3A patent/BR112014009941B1/pt active IP Right Grant
- 2012-10-26 EP EP22152099.2A patent/EP4052572A1/en active Pending
- 2012-10-26 PL PL17171524T patent/PL3272214T3/pl unknown
- 2012-10-26 DK DK19189533.3T patent/DK3590332T3/da active
- 2012-10-26 ES ES17171524T patent/ES2774488T3/es active Active
- 2012-10-26 HU HUE17171524A patent/HUE048511T2/hu unknown
-
2014
- 2014-04-03 IL IL231895A patent/IL231895B/en active IP Right Grant
- 2014-08-08 US US14/455,237 patent/US9585373B2/en active Active
- 2014-10-23 HK HK14110588.1A patent/HK1196999A1/xx unknown
-
2016
- 2016-01-11 IL IL243565A patent/IL243565A/en active IP Right Grant
- 2016-04-13 AU AU2016202317A patent/AU2016202317B2/en active Active
-
2017
- 2017-01-24 US US15/413,785 patent/US10219493B2/en active Active
- 2017-08-17 JP JP2017157497A patent/JP6652529B2/ja active Active
- 2017-09-04 HR HRP20171327TT patent/HRP20171327T1/hr unknown
- 2017-09-05 CY CY20171100934T patent/CY1119283T1/el unknown
-
2018
- 2018-02-27 AU AU2018201402A patent/AU2018201402C1/en active Active
- 2018-06-21 IL IL260209A patent/IL260209B/en active IP Right Grant
- 2018-07-24 HK HK18109591.4A patent/HK1250131A1/zh unknown
-
2019
- 2019-01-10 US US16/244,892 patent/US11219195B2/en active Active
- 2019-01-10 US US16/244,912 patent/US10986822B2/en active Active
-
2020
- 2020-02-24 HR HRP20200305TT patent/HRP20200305T1/hr unknown
- 2020-02-26 CY CY20201100178T patent/CY1122700T1/el unknown
-
2021
- 2021-01-22 AU AU2021200438A patent/AU2021200438B2/en active Active
- 2021-03-17 US US17/204,526 patent/US20210195878A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20220616T1 (hr) | Genetski modificirani miš koji eksprimira kimerne molekule glavnog kompleksa histokompatibilnosti (mhc) ii | |
HRP20191420T1 (hr) | Miševi koji su genetski modificirani s glavnim histokompatibilnim kompleksom | |
JP2014532412A5 (hr) | ||
HRP20191280T1 (hr) | Miševi koji eksprimiraju ko-receptore humanizirane t-stanice | |
US11183272B2 (en) | Method and systems for prediction of HLA class II-specific epitopes and characterization of CD4+ T cells | |
JP2014532411A5 (hr) | ||
BR112017005245A2 (pt) | animal não humano geneticamente modificado, métodos para produzir célula t, hibridoma de célula t, um ácido nucleico, um anticorpo específico, uma célula humana, um animal não humano geneticamente modificado e para induzir uma resposta imunológica, célula, hibridoma de célula t, ácido nucleico, anticorpo específico, receptor de antígeno quimérico, embrião não humano, locus de um receptor de antígeno quimérico, e, composição de ácidos nucleicos. | |
Chen et al. | Immunodominant CD4+ T-cell responses to influenza A virus in healthy individuals focus on matrix 1 and nucleoprotein | |
EA201590216A1 (ru) | Способы оценки пригодности трансдуцированных t-клеток для введения | |
Salomonsen et al. | Two CD1 genes map to the chicken MHC, indicating that CD1 genes are ancient and likely to have been present in the primordial MHC | |
BR112018012826A2 (pt) | método para gerar linfócitos, para gerar um tcr e tcr específico para gage-1 | |
MX2019009641A (es) | Receptores de la celula t que reconocen mhc de mage-a3 de clase ii-restringida. | |
FI3280257T3 (fi) | Humanisoituja t-soluvälitteisiä immuunivasteita ei-ihmiseläimillä | |
JP2016506761A5 (hr) | ||
CY1118124T1 (el) | Ανακατευθυνομενα, γενετικα τροποποιημενα ρυθμιστικα t-kyttapa και η χρηση τους στην καταστολη της αυτοανοσης και φλεγμονωδους ασθενειας | |
BR112015021819A2 (pt) | Tratamento de câncer utilizando receptor quimérico de antígeno humanizado anti-cd19 | |
Wang et al. | Classification of human leukocyte antigen (HLA) supertypes | |
Richards et al. | Direct ex vivo analyses of HLA-DR1 transgenic mice reveal an exceptionally broad pattern of immunodominance in the primary HLA-DR1-restricted CD4 T-cell response to influenza virus hemagglutinin | |
Warner et al. | Syrian hamsters as a small animal model for emerging infectious diseases: advances in immunologic methods | |
Reinherz | αβ TCR-mediated recognition: relevance to tumor-antigen discovery and cancer immunotherapy | |
Quadeer et al. | Epitopes targeted by T cells in convalescent COVID-19 patients | |
Seledtsov et al. | A possible role for Idiotype/anti-idiotype B–T cell interactions in maintaining immune memory | |
Flesch et al. | Altered CD8+ T cell immunodominance after vaccinia virus infection and the naive repertoire in inbred and F1 mice | |
Raghavan et al. | Strategies for the measurements of expression levels and half-lives of HLA class I allotypes | |
Xiong et al. | The enigma of CD4‐lineage specification |